(Press-News.org) More effective treatments for one of the deadliest forms of cancer are one step closer thanks to groundbreaking research from an international collaborative study.
Scientists from the Universities of Sheffield and Cologne have identified the dependencies of multiple Small Cell Lung Cancer (SCLC) types – paving the way for clinical trials of new targeted treatments which could revolutionise the current approach.
Around 40,000 people are diagnosed annually with lung cancer in the UK, and SCLC accounts for nearly one in five of all these cases.
Unfortunately, the prognosis for SCLC patients is very bleak – two thirds of people are diagnosed in the late stages of the disease when the five year survival rate with current treatments is less than five per cent.
But now researchers have discovered that survival of SCLC cells grown from human tumours relies upon a protein called Aurora kinase. This finding, published today (1 October 2012) in the journal: Proceeding of the National Academy of Sciences of the United States of America (PNAS), suggests that 'targeted' therapeutic strategies should focus on testing Aurora kinase inhibitors, several of which have already been developed by pharmaceutical companies.
The team also went on to show that Aurora kinase inhibitors are most effective at killing SCLC cells when the cells have high levels of the MYC cancer gene. This predicts that these drugs might be most beneficial for SCLC patients with a MYC gene amplification, which is found in up to seven per cent of people diagnosed with SCLC.
Dr Patrick Eyers, from the University of Sheffield's Institute for Cancer Studies, said: "A major goal of modern cancer research is to discover drugs that target vulnerabilities in specific cancer patient sub-populations. Current chemotherapy for SCLC kills cancerous cells and non-cancerous cells indiscriminately and results in severe side effects.
"However, revolutionary clinical trials have recently validated 'molecularly targeted' kinase inhibitors for treating cancers such as melanoma, leukaemia and non-small cell lung cancer.
"We have been studying Aurora kinase inhibitors for several years, and the remarkable vulnerability of some SCLC-derived cells to such drugs can hopefully be rapidly confirmed by careful stratification of SCLC patients and their enrolment in new clinical trials."
###
Notes to editors
For more information about the study contact Dr Patrick Eyers on p.eyers@sheffield.ac.uk or visit http://www.shef.ac.uk/oncology/staffprofiles/peyers
For the full paper visit http://www.PNAS.org/content/early/recent
The University of Sheffield
With nearly 25,000 students from 125 countries, the University of Sheffield is one of the UK's leading and largest universities. A member of the Russell Group, it has a reputation for world-class teaching and research excellence across a wide range of disciplines.
The University of Sheffield has been named University of the Year in the Times Higher Education Awards for its exceptional performance in research, teaching, access and business performance. In addition, the University has won four Queen's Anniversary Prizes (1998, 2000, 2002, 2007). These prestigious awards recognise outstanding contributions by universities and colleges to the United Kingdom's intellectual, economic, cultural and social life. Sheffield also boasts five Nobel Prize winners among former staff and students and many of its alumni have gone on to hold positions of great responsibility and influence around the world.
The University's research partners and clients include Boeing, Rolls Royce, Unilever, Boots, AstraZeneca, GSK, ICI, Slazenger, and many more household names, as well as UK and overseas government agencies and charitable foundations.
The University has well-established partnerships with a number of universities and major corporations, both in the UK and abroad. Its partnership with Leeds and York Universities in the White Rose Consortium has a combined research power greater than that of either Oxford or Cambridge.
For further information, please visit www.sheffield.ac.uk
For further information please contact: Amy Pullan, Media Relations Officer, on 0114 222 9859 or email a.l.pullan@sheffield.ac.uk
Breakthrough in understanding lung cancer vulnerabilities points the way to new targeted therapy
2012-10-02
ELSE PRESS RELEASES FROM THIS DATE:
Severely obese are fastest growing group of overweight Americans, study finds
2012-10-02
The proportion of Americans who are severely obese -- those people 100 pounds or more overweight -- continues to increase rapidly and much faster than those with moderate obesity, but the rate of growth has slowed, according to a new RAND Corporation study.
The RAND study found that from 2000 to 2010, the proportion of Americans who were severely obese rose from 3.9 percent of the population to 6.6 percent -- an increase of about 70 percent.
The findings mean that more than 15 million adult Americans are morbidly obese with a body mass index of 40 or more. The good ...
Meeting pigs' phosphorous requirements with fermented soybean meal
2012-10-02
Fermented soybean meal (FSBM), considered a promising substitute for fish meal in weanling pig diets because of its protein content, lower cost, and lack of anti-nutritional factors, may have an additional advantage. University of Illinois researchers recently found that pigs digest the phosphorous in FSBM better than the phosphorus in conventional soybean meal.
"Most of the P in soybean meal is bound to phytate, so it's not available to pigs," explained animal sciences professor Hans Stein.
Previous research by Stein's group found that pigs digest the phosphorous in ...
Marine animals could hold the key to looking young
2012-10-02
Sea cucumbers and sea urchins are able to change the elasticity of collagen within their bodies, and could hold the key to maintaining a youthful appearance, according to scientists at Queen Mary, University of London.
The researchers investigated the genes of marine creatures such as sea urchins and sea cucumbers, known as echinoderms. They found the genes for "messenger molecules" known as peptides, which are released by cells and tell other cells in their bodies what to do.
The study was published online in the journals PLOS One and General and Comparative Endocrinology. ...
Climate change cripples forests
2012-10-02
LOS ALAMOS, N.M., Oct. 1, 2012— Combine the tree-ring growth record with historic information, climate records and computer-model projections of future climate trends, and you get a grim picture for the future of trees in the southwestern United States. That's the word from a team of scientists from Los Alamos National Laboratory, the U.S. Geological Survey, University of Arizona, and several other partner organizations.
Described in a paper published in Nature Climate Change this week, "Temperature as a potent driver of regional forest drought stress and tree mortality," ...
No relief for relief workers: Humanitarian aid work raises risk of depression and anxiety
2012-10-02
Humanitarian workers are at significant risk for mental health problems, both in the field and after returning home. The good news is that there are steps that they and their employers can take to mitigate this risk.
These findings, from a new study by scientists at the U.S. Centers for Disease Control and Prevention (CDC) and collaborators, including Columbia University's Mailman School of Public Health, are published online in the journal PLOS ONE.
Researchers surveyed 212 international humanitarian workers at 19 NGOs. Prior to deployment, 3.8% reported symptoms of ...
Novel gene associated with Usher syndrome identified
2012-10-02
LEXINGTON, Ky. (Oct. 1, 2012) — Usher syndrome is a hereditary disease in which affected individuals lose both hearing and vision. The impact of Usher syndrome can be devastating. In the United States, approximately six in every 100,000 babies born have Usher syndrome.
Several genes associated with different types of Usher syndrome have been identified. Most of these genes encode common structural and motor proteins that build sensory cells in the eye and inner ear.
In a paper to be published in the November 2012 issue of Nature Genetics, a team of researchers from ...
Zinc deficiency mechanism linked to aging, multiple diseases
2012-10-02
CORVALLIS, Ore. – A new study has outlined for the first time a biological mechanism by which zinc deficiency can develop with age, leading to a decline of the immune system and increased inflammation associated with many health problems, including cancer, heart disease, autoimmune disease and diabetes.
The research was done by scientists in the Linus Pauling Institute at Oregon State University and the OSU College of Public Health and Human Sciences. It suggests that it's especially important for elderly people to get adequate dietary intake of zinc, since they may need ...
Popular antidepressant might prevent heart failure
2012-10-02
ANN ARBOR—A medication usually used to help treat depression and anxiety disorders has the potential to help prevent heart failure, according to researchers at the University of Michigan.
John Tesmer, research professor at the U-M Life Sciences Institute and professor in the Department of Pharmacology at the U-M Medical School, and his research team at the Tesmer lab found that paroxetine, a selective serotonin reuptake inhibitor (SSRI) sold under the name Paxil, inhibits G protein-coupled receptor kinase 2 (GRK2), a protein kinase that becomes over-expressed when people ...
Stem cells improve visual function in blind mice
2012-10-02
An experimental treatment for blindness, developed from a patient's skin cells, improved the vision of blind mice in a study conducted by Columbia ophthalmologists and stem cell researchers.
The findings suggest that induced pluripotent stem (iPS) cells – which are derived from adult human skin cells but have embryonic properties – could soon be used to restore vision in people with macular degeneration and other diseases that affect the eye's retina.
"With eye diseases, I think we're getting close to a scenario where a patient's own skin cells are used to replace retina ...
Fluoxetine increases aggressive behavior, affects brain development among adolescent hamsters
2012-10-02
BOSTON, Mass.-- Fluoxetine was the first drug approved by the FDA for major depressive disorder (MDD) in children and adolescents, and to this date, it remains one of only two selective serotonin reuptake inhibitors (SSRIs) registered for treatment of MDD in children and adolescents, despite reports that indicate this class of drugs is associated with side effects, such as agitation, hostility and aggression.
SSRIs have been amongst the most widely prescribed medications in psychiatry for over a decade. While there is a wealth of information regarding their effectiveness ...